MedPage Today  |  May 9, 2023

“The Orphan Drug Act comes from a good place, which is [to get companies] to invest in these rare diseases, since they’re not going to make a lot of money because the population is very small,” co-author Sean Tu, JD, PhD, of West Virginia University in Morgantown, told MedPage Today. “But we show that’s not true. They’re making a ton of money.”

Read more here.